| Bioactivity | PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM[1]. | ||||||||||||
| Invitro | PF-04418948 (2 μM; 90 min) inhibits prostaglandin E2 (PGE2)-induced increase in cAMP[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| In Vivo | PF-04418948 (oral gavage; 1, 3, and 10 mg/kg; once) attenuats the butaprost-induced cutaneous blood flow response[1]. Animal Model: | ||||||||||||
| Name | PF-04418948 | ||||||||||||
| CAS | 1078166-57-0 | ||||||||||||
| Formula | C23H20FNO5 | ||||||||||||
| Molar Mass | 409.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. af Forselles KJ, et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol. 2011 Dec;164(7):1847-1856. [2]. Birrell MA, et al. Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor. Br J Pharmacol. 2013 Jan;168(1):129-138. |